Financials
Financial year 2025
Groupement Pharmaceutique de l'Union Européenne from Brussel, company number BE0468971838, closed financial year 2025 with a result of € -1,939 after tax. For that financial year Groupement Pharmaceutique de l'Union Européenne recorded a gross margin of € 562,251 and equity of € 1.8 million. Compared with financial year 2024, the result moved from € 110,714 to € -1,939. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 1.8 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1,939
▼ still € 110,714 profit in 2024
Profit after tax over the fiscal year.
€ 979,890
▼ 9% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
€ 518,257
▲ 2% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 26,486
▼ 12% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,389
▼ 73% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 112,029
▲ 51% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 607,194 | € 698,183 | € 670,824 | € 562,251 | ▼ 16% |
| Profit after taxes | € 81,513 | € 122,072 | € 110,714 | € -1,939 | ▼ € 112,653 |
| Equity | € 1,520,817 | € 1,642,889 | € 1,753,603 | € 1,751,663 | |
| Total debts | € 125,017 | € 101,175 | € 909,069 | € 942,257 | ▲ 4% |
| Cash | € 896,178 | € 999,019 | € 1,079,448 | € 979,890 | ▼ 9% |
| Land & buildings | € 708,234 | € 690,711 | € 673,188 | € 656,743 | ▼ 2% |
| Retained profit | € 967,861 | € 1,089,933 | € 1,200,646 | € 1,198,707 | |
| Balance sheet total | € 1,645,835 | € 1,744,064 | € 2,662,671 | € 2,693,921 | ▲ 1% |
| Employees (FTE) | 4.3 | 4.6 | 4.4 | - |
By gross margin, Groupement Pharmaceutique de l'Union Européenne ranks 82nd of 130 companies with main activity “Activiteiten van bedrijfs- en werkgeversorganisaties” in Brussel that publish figures (fiscal year 2025).
Key figures of Groupement Pharmaceutique de l'Union Européenne, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Groupement Pharmaceutique de l'Union Européenne the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Groupement Pharmaceutique de l'Union Européenne?
What happened at Groupement Pharmaceutique de l'Union Européenne in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Apostolos Valtas stepped down as director. NBB
- Jesus Aguilar Santamaria stepped down as director. NBB
- Maria Teresa Moreira Da Cruz stepped down as director. NBB
- Ana Soldo stepped down as director. NBB
- Ly Rootslane stepped down as director. NBB
- Janusz Konstanty Mikolaj stepped down as director. NBB
- Clare Fitzell stepped down as director. NBB
- Mathias Steffen Arnold stepped down as director. NBB
In short
From € 81,513 profit in 2022 to € 1,939 loss in 2025.
Paid € 4,354 in corporate taxes since 2022.
Best year ever: 2023, with € 122,072 profit.
On average € 152,500 of value added per employee in 2024.
Management
Directors
According to the 2025 annual accounts
Silviu Constantinescu
Director
since 2024 · until 2025
Claude Pfeiffer-Hosert
Director
since 2025 · until 2025
Apostolos Valtas
Director
since 2026 · until 2026
Jesus Aguilar Santamaria
Director
since 2026 · until 2026
Maria Teresa Moreira Da Cruz
Director
since 2026 · until 2026
Ana Soldo
Director
since 2026 · until 2026
Ly Rootslane
Director
since 2026 · until 2026
Janusz Konstanty Mikolaj
Chairman of the board
since 2026 · until 2026
Clare Fitzell
Director
since 2026 · until 2026
Mathias Steffen Arnold
Director
since 2026 · until 2026
Martin Kopecky
Director
since 2026 · until 2026
Dimitar Marinov
Director
since 2024 · until 2025
Establishments
Establishment units
Physical locations of this company
Luxemburgstraat 19-21
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Brussel
Same main activity (Activiteiten van bedrijfs- en werkgeversorganisaties), 265 active companies in Brussel, largest first.
VLAAMSE VERENIGING VOOR ICT-PERSONEEL
€ 50.6 million revenue · 2024
Vlaams Centrum voor Agro- en Visserijmarketing
€ 17 million revenue · 2025
Association Pharmaceutique Belge-Algemene Pharmaceutische Bond
€ 12.4 million revenue · 2023
€ 10.4 million revenue · 2025
€ 9.5 million revenue · 2025
€ 8 million revenue · 2025
Details
- Company number
- 0468.971.838
- VAT number
- BE 0468.971.838
- Registered office
- Luxemburgstraat 19-21, 1000 Brussel
- Names & denominations
- Groupement Pharmaceutique de l'Union Européenne · GPEU
- Enterprise type
- Rechtspersoon
- Legal form
- International non-profit association
- Legal situation
- Normale toestand
- Start date
- 13 January 2000
- Peppol
- Active · Active since 12 Mar 2026
- Activities · NACE
Activiteiten van bedrijfs- en werkgeversorganisaties
Bedrijfs- en werkgeversorganisaties
Activiteiten van beroepsorganisaties
Beroepsorganisaties